Home The Action MC Substitutes/Other Ioanna Andreadou (EL)

Wed,22Feb2017

Dr. Ioanna Andreadou

Assistant Professor of Pharmacology
Department of Pharmaceutical Chemistry,
School of Pharmacy,
University of Athens,
Panepistimiopolis, Zografou,
15771, Athens, Greece

T: 302107274827
F: 302107274747  
E: This email address is being protected from spambots. You need JavaScript enabled to view it.

Research Interests

  • Cardiovascular pharmacology
  • Myocardial ischemic pre- and postconditioning
  • Oxidative stress in ischemia – reperfusion injury
  • Molecular toxicology
  • Relationship between structure and pharmacological activities

Selected Recent Publications

  • Ι. Andreadou*, D. Farmakis, Ε. Prokovas, F. Sigala, Α. Zoga, et al. Short-term statin administration in hypercholesterolemic rabbits resistant to postconditioning: effects on infarct size, endothelial nitric oxide synthase and nitro-oxidative stress. Cardiovasc Res, 94: 501-509, 2012.
  • E.K. Iliodromitis, I. Andreadou*, E. Prokovas, A. Zoga, D. Farmakis, et al. Simvastatin in contrast to postconditioning reduces infarct size in hyperlipidemic rabbits: possible role of oxidative/nitrosative stress. Basic Res Cardiol, 105:193-203, 2010.
  • I. Ikonomidis, J.P. Lekakis, M. Nikolaou, I. Paraskevaidis, I. Andreadou, et al.  Inhibition of interleukin-1 by Anankira improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation, 117:2662-2269, 2008.
  • I. Andreadou*, F. Sigala, E. K. Iliodromitis, M. Papaefthimiou, C. Sigalas, N. Aligiannis, P. Savvari, V. Gorgoulis, E. Papalabros, D. Th. Kremastinos. Acute doxorubicin cardiotoxicity is successfully treated with the phytochemical oleuropein through suppression of oxidative and nitrosative stress. J Mol Cell Cardiol, 42: 549-558, 2007.
  • I. Andreadou*, E. K. Iliodromitis, K. Tsovolas, I. K. Aggeli, A. Zoga, et al.  Acute administration of Vitamin E triggers preconditioning via KATP channels and cyclic-GMP without inhibiting lipid peroxidation. Free Radic Biol Med, 41: 1092-1099, 2006.

ESF

COST

POLICY STATEMENT: Biomedicine and Molecular Biosciences Action BM1005 is funded by COST, through its implementing agent the European Science Foundation.